Return on Investments: An indicator of how profitable a company is relative to its assets invested by shareholders and long-term bond holders. Calculated by dividing a company's operating earnings by its long-term debt and shareholders equity. Calculated as: Income from Continuing Operations / (Total Long-Term Debt + Shareholders Equity)
Contineum Therapeutics, Inc. (CTNM) had Return on Investments of -21.34% for the most recently reported fiscal year, ending 2024-12-31.
| Income Statement Financials | |
-- |
|
$-42.26M |
|
-- |
|
-- |
|
$50.89M |
|
$-50.89M |
|
$8.64M |
|
$-42.26M |
|
$-42.26M |
|
$-42.26M |
|
$-42.26M |
|
$-42.26M |
|
$-42.26M |
|
$-50.89M |
|
$-50.64M |
|
19.35M |
|
19.35M |
|
$-2.18 |
|
$-2.18 |
|
| Balance Sheet Financials | |
$206.39M |
|
$0.99M |
|
$6.46M |
|
$212.85M |
|
$9.97M |
|
-- |
|
$4.81M |
|
$14.78M |
|
$198.07M |
|
$198.07M |
|
$198.07M |
|
25.85M |
|
| Cash Flow Statement Financials | |
$-32.84M |
|
$-69.74M |
|
$109.00M |
|
$15.53M |
|
$21.94M |
|
$6.42M |
|
$6.80M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
20.69 |
|
-- |
|
-- |
|
-- |
|
0.01 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-33.34M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-21.34% |
|
-21.34% |
|
-19.85% |
|
|
Return on Investments |
-21.34% |
$7.66 |
|
$-1.72 |
|
$-1.70 |
|